Trial Profile
The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Mar 2018 New trial record